Applications of Fmoc-L-Citrulline in Industrial Manufacturing

We supply Fmoc-L-Citrulline for advanced peptide synthesis and specialized uses in regulated industrial sectors. As a direct manufacturer, we support downstream users with consistent quality and technical expertise to meet stringent process and compliance demands. The following application scenarios reflect established, real-world sectors where Fmoc-L-Citrulline forms a vital link in modern production lines.

1. Solid-Phase Peptide Synthesis (SPPS) for Research-Grade Peptides

Biotechnology R&D laboratories and custom peptide production facilities incorporate our raw material as a temporary N-terminal protecting group to construct complex peptides and oligopeptides. It participates in automated SPPS procedures using Fmoc chemistry, offering clean deprotection steps and minimizing side reactions, which is critical for analytical reproducibility and sequence fidelity. Our product meets purity and safety parameters required for molecular biology workflows.

Industry compliance standards

• ISO 9001:2015 (Quality Management Systems)
• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• European Pharmacopoeia 11.0/USP monographs (if used in analytical reference peptide preparation)
• OECD GLP (Good Laboratory Practice) for regulated test environments

Typical usage ratio

• 0.5 to 2.0 equivalents per amino acid coupling cycle; quantity varies according to resin loading and target sequence length

Downstream process integration

• Charged as a protected amino acid monomer during initial resin loading and aspartic acid side-chain introduction steps
• Enters coupling and deprotection cycles on automated peptide synthesizers

Final product types

• Research-grade custom peptides (milligram to gram scale)
• Amino acid derivatives for molecular toolkits
• Reference peptides for analytical or calibration standards

2. GMP Peptide Active Pharmaceutical Ingredient (API) Manufacturing

API facilities use our raw material to introduce non-canonical residues into therapeutic peptide sequences under GMP controls. It facilitates step-wise peptide assembly where modifications such as arginine deimination are required. The controlled release of the Fmoc group during synthesis supports regulatory documentation and rigorous in-process monitoring essential for drug development and commercial production.

Industry compliance standards

• US FDA 21 CFR Part 210/211 (Current Good Manufacturing Practice in Manufacturing)
• EU EudraLex Volume 4 – GMP for APIs
• ICH Q7 guidance (GMP for Active Pharmaceutical Ingredients)
• Ph. Eur., USP, or JP specifications (if included in the registered drug master file)

Typical usage ratio

• 1.0 to 1.2 equivalents per incorporation step; ratio controlled tightly by in-line HPLC monitoring for regulatory batch consistency

Downstream process integration

• Integrated at the amino acid coupling stage in automated or semi-automated peptide synthesizers
• Processed through repeated cycles of coupling, washing, and Fmoc deprotection, maintaining traceability in batch records

Final product types

• Peptide APIs for injectable drugs
• Therapeutic oligopeptides for clinical use
• Peptide candidates for clinical trial supply

3. Diagnostic Peptide Kit Assembly

Specialty reagents manufacturers incorporate our ingredient into bioconjugation ready peptide fragments for use in in vitro diagnostics (IVD). Accurate Fmoc-protection improves sequence resolution when preparing antigenic peptides, facilitating consistent coating of microtiter plates, latex beads, or biosensor surfaces. Quality control relies on batch-to-batch reproducibility of peptides functionalized with citrullinated residues for high-sensitivity assays.

Industry compliance standards

• ISO 13485 (Quality Management Systems for Medical Devices)
• IVDR (EU Regulation 2017/746 on in vitro diagnostic medical devices)
• US FDA 21 CFR Part 820 (Quality System Regulation for Medical Devices)
• CE marking for IVD raw material traceability

Typical usage ratio

• 0.8 to 1.5 equivalents per peptide coupling cycle, with ratio chosen based on planned conjugation density and surface coupling efficiency

Downstream process integration

• Added to pre-loaded resin during peptide sequence elongation
• Precursor fragments are cleaved, purified, then conjugated to carrier proteins or beads for kit assembly

Final product types

• Peptidic antigens for ELISA or lateral flow tests
• Synthetic substrates or calibrators for autoimmune diagnostic kits
• Peptide-biomolecule conjugates for multiplex immunoassays

4. Peptidomimetic Chemical Probe Synthesis

Specialty chemical producers and life science tool manufacturers leverage our protected L-citrulline for the assembly of peptidomimetic probes, enabling structure-activity studies in academic and pharmaceutical research settings. The material allows integration of citrulline analogues at defined points in probe backbones and supports post-synthetic labeling when required for target binding studies or imaging.

Industry compliance standards

• ISO 9001:2015 (Quality management for research chemical production)
• OECD GLP (where chemical probes support preclinical safety studies)
• Research Use Only (RUO) classification regulatory declarations for export
• MSDS conformity to GHS/CLP standards for laboratory safety

Typical usage ratio

• 1.0 equivalent per labeled residue inclusion; may be increased for multiply modified analogues or when supporting conjugation reactions downstream

Downstream process integration

• Incorporated in manual or automated SPPS trays during probe sequence construction
• Allows subsequent selective deprotection and functionalization for label attachment or surface immobilization

Final product types

• Synthetic peptidomimetic probes for enzyme binding studies
• Fluorescent or affinity-tagged peptide analogs for target identification
• Peptide-based chemical tool compounds for in vitro screening platforms